Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 103,200 shares, an increase of 47.9% from the September 15th total of 69,800 shares. Currently, 3.0% of the shares of the company are short sold. Based on an average daily trading volume, of 1,640,000 shares, the short-interest ratio is currently 0.1 days.

Alzamend Neuro Stock Performance

ALZN opened at $1.66 on Friday. Alzamend Neuro has a 1-year low of $1.40 and a 1-year high of $33.57. The stock’s fifty day simple moving average is $2.19 and its 200 day simple moving average is $4.53.

Alzamend Neuro (NASDAQ:ALZN) last released its quarterly earnings data on Wednesday, September 11th. The company reported ($1.25) EPS for the quarter, beating the consensus estimate of ($2.38) by $1.13. As a group, research analysts expect that Alzamend Neuro will post -14.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Virtu Financial LLC bought a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned 0.38% of Alzamend Neuro as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.